BioWorld

Feb. 8, 2007

View Archived Issues

BioLineRx Prices $50M IPO, Listing On Tel Aviv Exchange

Israeli drug development firm BioLineRx Ltd. gained a listing on the Tel Aviv Stock Exchange and brought in $50 million in an oversubscribed initial public offering. (BioWorld Today) Read More

Proacta Completes $35M Series B For Hypoxia Trials

Read More

Encysive Sells $60M In Notes Secured By Argatroban Royalties

Read More

Biogen Idec Testing Targeted MAB In Pivotal CLL Study

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More

Clinic Roundup

Read More